These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32783166)

  • 1. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Shimoda K; Takahashi N; Kirito K; Iriyama N; Kawaguchi T; Kizaki M
    Int J Hematol; 2020 Sep; 112(3):268-291. PubMed ID: 32783166
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytogenetics and genomics in CML and other myeloproliferative neoplasms.
    Kreipe HH; Schlegelberger B
    Best Pract Res Clin Haematol; 2024 Jun; 37(2):101552. PubMed ID: 39098796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
    Fontana D; Zambrotta GPM; Scannella A; Piazza R; Gambacorti-Passerini C
    Ann Hematol; 2024 May; 103(5):1561-1568. PubMed ID: 38321229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Abdel-Wahab O; Rampal R; Mesa R; Koschmieder S; Levine R; Hehlmann R; Saglio G; Barbui T; Van Etten RA
    Leuk Lymphoma; 2016 Jul; 57(7):1517-26. PubMed ID: 27240645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.
    Yao S; Na L; Liangding H
    Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.
    Karantanos T; Jain T; Moliterno AR; Jones RJ; DeZern AE
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
    Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
    Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group.
    Athale U; Hijiya N; Patterson BC; Bergsagel J; Andolina JR; Bittencourt H; Schultz KR; Burke MJ; Redell MS; Kolb EA; Johnston DL
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27827. PubMed ID: 31330093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
    Cross NCP; Ernst T; Branford S; Cayuela JM; Deininger M; Fabarius A; Kim DDH; Machova Polakova K; Radich JP; Hehlmann R; Hochhaus A; Apperley JF; Soverini S
    Leukemia; 2023 Nov; 37(11):2150-2167. PubMed ID: 37794101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hen or the Egg: Inflammatory Aspects of Murine MPN Models.
    Jutzi JS; Pahl HL
    Mediators Inflamm; 2015; 2015():101987. PubMed ID: 26543325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.
    Baranwal A; Basmaci R; He R; Viswanatha D; Greipp P; Murthy HS; Foran J; Palmer J; Hogan WJ; Litzow MR; Hefazi M; Mangaonkar A; Shah MV; Al-Kali A; Alkhateeb HB
    Blood Adv; 2024 Feb; 8(3):562-570. PubMed ID: 38011614
    [No Abstract]   [Full Text] [Related]  

  • 12. Mathematical modelling, selection and hierarchical inference to determine the minimal dose in IFNα therapy against myeloproliferative neoplasms.
    Hermange G; Vainchenker W; Plo I; Cournède PH
    Math Med Biol; 2024 Jun; 41(2):110-134. PubMed ID: 38875109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].
    Chinese Society of Hematology, Chinese Medical Association
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):353-364. PubMed ID: 32536131
    [No Abstract]   [Full Text] [Related]  

  • 14. The psychological needs of adolescents and young adults with a diagnosis of myeloproliferative neoplasms: a systematic scoping review of the literature.
    Houlihan T; Fortune DG; Keohane C; Richards HL
    Leuk Lymphoma; 2024 May; 65(5):679-683. PubMed ID: 38324010
    [No Abstract]   [Full Text] [Related]  

  • 15. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?
    Garcia-Horton A; Lipton JH
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1421-1428. PubMed ID: 33022650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Deininger MW; Shah NP; Altman JK; Berman E; Bhatia R; Bhatnagar B; DeAngelo DJ; Gotlib J; Hobbs G; Maness L; Mead M; Metheny L; Mohan S; Moore JO; Naqvi K; Oehler V; Pallera AM; Patnaik M; Pratz K; Pusic I; Rose MG; Smith BD; Snyder DS; Sweet KL; Talpaz M; Thompson J; Yang DT; Gregory KM; Sundar H
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1385-1415. PubMed ID: 33022644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Leleu X; Guilhot F; Chomel JC
    Cancer; 2021 Mar; 127(6):976-978. PubMed ID: 33095912
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognostic factor.
    Llamas-Velasco M; Ovejero-Merino E; García-Diez A; Requena L; Daudén E; Steegmann JL
    Dermatol Ther; 2020 Nov; 33(6):e14428. PubMed ID: 33073453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
    Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
    Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.